The Expanding Role of Fludarabine in Hematologic Malignancies

References

• Grever M. R., Leiby J., Kraut E., Metz E., Neidhart J., Balcerzak S., Malspeis L. A comprehensive phase I and II clinical investigations of fludarabine phosphate. Semin. Oncol. 1990; 17(Suppl 8)39–48
   PubMedGoogle Scholar
• Von Hoff D. D. Phase I clinical trials with fludarabine phosphate. Semin. Oncol. 1990; 17: 33–38
   PubMed Web of Science ®Google Scholar
• Grever M. R., Coltman C. A., Files J. C., et al. Fludarabine monophosphate in chronic lymphocytic leukemia. Blood 1986; 68: 223a, abstract
   Google Scholar
• Keating M. J., Kantarjian H., O'Brien S., et al. Fludarabine: A new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J. Clin. Oncol 1991; 9: 44–49
   PubMed Web of Science ®Google Scholar
• Keating M. J., Kantarjian H., Talpaz M., et al. Fludarabine: A new agent with major activity against chronic lymphocytic leukemia. Blood 1989; 74: 19–25
   PubMed Web of Science ®Google Scholar
• Redman J. R., Cabanillas F., Velasquez W. S., et al. Phase II trial of fludarabine phosphate in lymphoma: An effective new agent in low-grade lymphoma. J. Clin. Oncol 1992; 10: 790–794
   PubMed Web of Science ®Google Scholar
• Hochster H. S., Kim K., Green M. D., et al. Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: Results of an Eastern Cooperative Oncology Group study. J. Clin. Oncol 1992; 10: 28–32
   PubMed Web of Science ®Google Scholar
• Plunkett W., Huang P., Gandhi V. Metabolism and action of fludarabine phosphate. Semin. Oncol 1990; 17: 3–17
   PubMed Web of Science ®Google Scholar
• Grever M. R., Kopecky K. J., Coltman C. A., Files J. C., Greenberg B. R., et al. Fludarabine monophosphate: A potentially useful agent in chronic lymphocytic leukemia. Nouvell Revue Francaise d'Hematologic 1988; 30: 457–459
   PubMed Web of Science ®Google Scholar
• Cheson B. D., Bennett J. M., Rai K. R., Grever M. R., Kay N. E., Schiffer C. A., Oken M. M., Keating M. J., Boldt D. H., Kempin S. J., Foon K. A. Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the National Cancer Institute Sponsored Working Group. Am. J. Hematol. 1988; 29: 152–163
   PubMed Web of Science ®Google Scholar
• Kemena A., O'Brien S., Kantarjian H., Robertson L., Koller C., Beran M., Estey E., Plunkett W., Lerner S., Keating M. Phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose schedule. Leukemia Lymphoma 1993; 10: 187–193
   PubMed Web of Science ®Google Scholar
• Robertson L. E., O'Brien S., Koller C., et al. A three-day schedule of fludarabine in chronic lymphocytic leukemia (CLL). Blood 1992; 80(Suppl 1)47a, abstract
   Google Scholar
• O'Brien S., Kantarjian H., Beran M., Smith T., Koller C., Estey E., Robertson L. E., Lemer S., Keating M. Results of flu-darabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 1993; 82: 1695–1700
   PubMed Web of Science ®Google Scholar
• Robertson L. E., Huh Y. O., Butler J. J., Pugh W. C., Hirsch-Ginsberg C., Stass S., Kantarjian H., Keating M. J. Response assessment in chronic lymphocytic leukemia after flu-darabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis. Blood 1992; 80: 29–36
   PubMed Web of Science ®Google Scholar
• Keating M. J. Immunosuppression with purine analogues—–the flip side of the gold coin. Ann. Oncol. 1993; 4: 347–348
   PubMed Web of Science ®Google Scholar
• Keating M. J., O'Brien S., Kantarjian H., Plunkett W., Estey E., Roller C., Beran M., Freireich E. J. Long-term follow-up of patients with chronic lymphocytic leukemia treated with flu-darabine as a single agent. Blood 1993; 81: 2878–2884
   PubMed Web of Science ®Google Scholar
• Puccio C. A., Mittelman A., Lichtman S. M., Silver R. T., Budman D. R., Ahmed T., Feldman E. J., Coleman M., Arnold P. M., Arlin Z. A., Chun H. G. A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia. J. Clin. Oncol. 1991; 9: 1562–1569
   PubMed Web of Science ®Google Scholar
• Fenchel K., Bergmann L., Jahn B., Mitrou P., Hoelzer D. Fludarabine phosphate in refractory chronic lymphocytic leukemia. Onkologie 1991; 14(Suppl 2)190
   Google Scholar
• Hiddeman W., Rottman R., Wormann P., Theil A., Essink M., et al. Treatment of advanced chronic lymphocytic leukemia by fludarabine: Results of a clinical phase II study. Ann. J. Hematol. 1991; 63: 1–1
   Web of Science ®Google Scholar
• MacKenzie M. R., Fudenberg H. H. Macroglobulinemia—An analysis of forty patients. Blood 1972; 39: 874–889
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., Alexanian R., Koller C. A., Kurzrock R., Keating M. J. Fludarabine therapy in macroglobulinemic lymphoma. Blood 1990; 75: 1928–1931
   PubMed Web of Science ®Google Scholar
• Dimopoulos M. A., O'Brien S., Kantarjian H., Pierce S., Delasalle K., Barlogie B., Alexanian R., Keating M. J. Fludarabine therapy in Waldenstrom's macroglobulinemia. Am. J. Med. 1993; 95: 49–52
   PubMed Web of Science ®Google Scholar
• Whelan J. S., Ganjoo R., Johnson P. W.ML, Rohatiner A. Z. S., Lister T. A. Treatment of low grade non-Hodgkin's lymphomas with fludarabine. Leukemia Lymphoma 1993; 10: 35–37
   PubMedGoogle Scholar
• Zinzani P. L., Lauria F., Rondelli D., Benfenati D., Raspadori D., Bocchia M., Bendani M., Zaja F., Fanin R., Russo D., Galieni P., Tura S. Fludarabine: An active agent in the treatment of previously treated low grade non-Hodgkin's lymphoma. Ann. Oncol. 1993; 4: 575–578
   PubMed Web of Science ®Google Scholar
• Von Hoff D. D., Dahlberg S., Hartstock R. J., Eyre H. J. Activity of fludarabine monophosphate in patients with advanced mycosis fungoides. A Southwest Oncology Group Study. J. Natl. Cancer Inst. 1990; 82: 1353–1355
   PubMed Web of Science ®Google Scholar
• McLaughlin P., Swan F., Hagemeister F., et al. Phase I study of the combination fludarabine, mitoxantrone, and dexam-ethasone in low grade lymphoma (LGL). Proc. Amer. Assoc. Cancer Res. 1992; 33: 228, abstract
   Google Scholar
• Gandhi V., Plunkett W. Modulation of arabinosyl nucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res. 1988; 48: 329–334
   PubMed Web of Science ®Google Scholar
• Gandhi V., Robertson L. E., Keating M. J., et al. Combination of fludarabine & ara-C for treatment of CLL. Clinical efficacy and modulation of ara-CTP pharmacology. Blood 1992; 80(Suppl 1)47a, abstract
   Google Scholar
• Estey E., Plunkett W., Gandhi V., et al. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leukemia Lymphoma 1993; 9: 343–350
   PubMed Web of Science ®Google Scholar
• Yang L. Y., Trujillo J. M., Keating M. J., et al. Effect of fludarabine on the tumoricidal synergy produced by the combination of arabinosylcytosine and cisplatin in human LoVo colon carcinoma cells. Proc. Amer. Assoc. Cancer Res. 1992; 33: 443, abstract
   Google Scholar
• Yang L. Y., Li L., Trujillo J. M., et al. Fludarabine synergizes cisplatin cytotoxicity in LoVo human colon carcinoma cells by inhibiting repair of cisplatin-induced DNA damage. Proc. Amer. Assoc. Cancer Res. 1993; 34: 347, abstract
   Google Scholar
• Robertson L. E., Kantarjian H., O'Brien S., et al. Cisplatin, fludarabine, and ara-C: A regimen for advanced fludarabine refractory chronic lymphocytic leukemia. Proc. Amer. Soc. Clin. Oncol. 1993; 12: 308, abstract
   Google Scholar
• Gandhi V., Estey E., Keating M. J., et al. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J. Clin. Oncol. 1993; 11: 116–124
   PubMed Web of Science ®Google Scholar
• Keating M., Smith T., Kantarjian H., Cork A., Walters R., Trujillo J., McCredie K., Gehan E., Freireich E. Cytogenetic pattern in acute myelogenous leukemia. A major reproducible determinant of outcome. Leukemia 1988; 2: 403–412
   PubMed Web of Science ®Google Scholar
• Koistinen P., Wang C., Curtis J. E., et al. Granulocyte macrophage colony stimulating factor and interieukin-3 protect leukemic blast cells from ara-C toxicity. Leukemia 1991; 5: 789–795
   PubMed Web of Science ®Google Scholar
• Plunkett W., Gandhi V., Huang P., et al. Fludarabine: Pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin. Oncol. 1993; 20: 2–12
   PubMed Web of Science ®Google Scholar
• Gregoire V., Hunter N., Milas L., et al. Enhancement of radiation response by fludarabine in murine tumor models. Proc. Amer. Assoc. Cancer Res. 1992; 33: 85, abstract
   Google Scholar